PF-06823859
Sponsors
Pfizer Inc., Pfizer
Conditions
Active Cutaneous Lupus Erythematosus (CLE) or Systemic Lupus Erythematosus (SLE) With Cutaneous ManifestationsActive Idiopathic Inflammatory Myopathies (Including Dermatomyositis or Polymyositis)HealthyLupus Erythematosus, CutaneousLupus Erythematosus, SystemicMyositis
Phase 1
Evaluation Of Safety, Tolerability And Pharmacokinetics Of Single And Multiple Doses Of Compound PF-06823859
CompletedNCT02766621
Start: 2016-05-27End: 2017-09-26Updated: 2017-11-17
Investigation of Safety, Tolerability, Immunogenicity and Pharmacokinetics of Single-Dose of PF-06823859 in Japanese Healthy Participants
CompletedNCT05037409
Start: 2021-09-28End: 2022-03-27Updated: 2023-12-15
Phase 2
A Study to Learn About the Study Medicine (PF-06823859) in Adults With Active CLE or SLE With Skin Symptoms.
TerminatedNCT05879718
Start: 2023-07-07End: 2025-11-18Updated: 2026-03-13
C0251013 - A PHASE 2, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE CLINICAL EFFECT, PHARMACODYNAMIC, PHARMACOKINETIC AND SAFETY PROFILE OF PF-06823859 IN ADULT PARTICIPANTS WITH ACTIVE CLE OR SLE WITH CUTANEOUS MANIFESTATIONS
CompletedCTIS2023-503343-33-00
Start: 2023-12-21End: 2025-10-08Target: 10Updated: 2025-10-10
Phase 3
A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)]
RecruitingNCT05895786
Start: 2023-05-20End: 2027-07-28Target: 318Updated: 2026-04-02
C0251006 - A PHASE 3, MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF-06823859 IN PARTICIPANTS WITH ACTIVE IDIOPATHIC INFLAMMATORY MYOPATHIES (INCLUDING PARTICIPANTS WITH ACTIVE DERMATOMYOSITIS OR POLYMYOSITIS)
RecruitingCTIS2022-502739-20-00
Start: 2023-11-16Target: 79Updated: 2025-12-17